Pontin is a critical regulator for AML1-ETO-induced leukemia.

Area of Science:

• Hematology
• Molecular Biology
• Cancer Research

Background:

• The t(8;21) translocation creates the oncogenic AML1-ETO fusion protein, a frequent driver in acute myeloid leukemia (AML).
• Understanding cooperating genes is crucial for targeting AML1-ETO's oncogenic activity.
• Drosophila models have proven effective for studying AML1-ETO's leukemogenic mechanisms.

Purpose of the Study:

• To identify genes essential for AML1-ETO's oncogenic functions using a Drosophila RNA interference screen.
• To investigate the role of identified genes in human t(8;21)(+) AML.
• To elucidate the mechanism by which AML1-ETO promotes leukemogenesis.

Main Methods:

• Conducted an in vivo RNA interference screen in Drosophila to find suppressors of AML1-ETO activity.
• Assessed the impact of PONTIN/RUVBL1 inhibition on human t(8;21)(+) or AML1-ETO-expressing leukemic cells.
• Performed transcriptome analysis in Kasumi-1 cells to correlate PONTIN and AML1-ETO gene expression.
• Investigated the effect of PONTIN depletion on cell cycle progression and leukemic self-renewal.

Main Results:

• Identified pontin/RUVBL1 as a critical gene required for AML1-ETO-induced lethality and blood cell proliferation in Drosophila.
• Demonstrated that PONTIN inhibition significantly impaired the growth of human AML1-ETO-expressing leukemic cells.
• Showed that AML1-ETO directly promotes PONTIN transcription.
• Transcriptome analysis revealed PONTIN regulates genes involved in cell cycle progression, and its depletion caused cell cycle arrest and inhibited self-renewal.

Conclusions:

• Upregulation of PONTIN by AML1-ETO is a key mechanism contributing to the oncogenic growth of t(8;21) AML cells.
• Targeting PONTIN represents a potential therapeutic strategy for AML1-ETO-driven leukemia.
• This study highlights the conserved role of PONTIN in AML pathogenesis across species.